Fidelity and corporate-backed Flagship Ventures provided the funding for the biotechnology company, which has now secured more than $60m altogether.
US-based biotechnology company Pronutria Biosciences closed a $39m series C round yesterday that was led by diversified financial services provider Fidelity Mangement and Research.
The round also included Flagship Ventures, the venture capital firm that closed a $537m fund in March this year, following investments by pharmaceutical company AstraZeneca, nutritional therapy developer Nestlé Health Science and agribusiness Bayer CropScience.
Additional unnamed investors also participated in the round. Pronutria is developing treatments for a range of conditions, including muscle, metabolic, neurological…
